Five Recent Deals Show ADCs Aren’t Cooling Off For Summer

 
• By Joseph Haas

While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.

summer_cloudsresized.jpg
A review of this summer's dealmaking sees a continued interest in ADCs

More from Deals

More from Business